Full-Time

Director – Payer Account Management

Updated on 3/13/2025

Axsome Therapeutics Inc

Axsome Therapeutics Inc

201-500 employees

Develops therapies for CNS disorders

Compensation Overview

$170k - $210kAnnually

+ Annual Bonus + Equity

Senior

Dallas, TX, USA

Strong preference for candidates that live within the Central Region.

Category
Strategic Account Management
Sales & Account Management
Required Skills
Marketing
Requirements
  • Bachelor's degree in business, marketing, economics, or health sciences
  • Minimum of 6 years of successful Payer Account Management experience required
  • Strong understanding of the payer landscape and how payer decision making impacts providers and their patients
  • Demonstrated experience gaining formulary access for a launch product at regional payer and PBM accounts
  • Strong preference for candidate to live within the territory
Responsibilities
  • Ensure disciplined and effective communication with key payer stakeholders and decision makers
  • Understand dynamics of Payer (PBM and Plan) relationships, and key decision makers
  • Network across the industry and each account
  • Execute the payer engagement strategy and leverage Payer Value Proposition to obtain appropriate access/formulary position among target accounts
  • Profile key payer accounts to assess formulary review process, formulary coverage policies, utilization management deployed for the applicable therapeutic areas, and geographic coverage areas
  • Identify and address potential barriers to access proactively to ensure launch product is well positioned for formulary and P&T reviews
  • Identify competitive threats and develop strategies to ensure optimal coverage for Axsome Therapeutics’ portfolio of products
  • Lead pull-though initiatives that capitalize on formulary wins and lead push-though efforts in areas with access challenges
  • Ensure compliance with Axsome Therapeutics’ corporate policies and procedures and U.S. healthcare laws and regulations
Desired Qualifications
  • Negotiation experience, preferably in competitive primary care therapeutic areas
  • Analytical mindset and history of leveraging HEOR data to articulate a value story that ensures rapid formulary coverage of launch products
  • A problem-solving mindset with demonstrated “lean-forward” approach and ability to think critically
  • Previous product launch experience, preferably in the CNS space
  • Familiarity with current legal and regulatory landscape pertinent to the industry
  • Previous experience at a small biopharmaceutical company
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain to help regulate mood. This drug has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, which speeds up its development process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and clinical trials. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Company Size

201-500

Company Stage

IPO

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased investment in CNS treatments boosts Axsome's pipeline potential.
  • FDA's fast-tracking emphasis could expedite Axsome's drug approvals, especially AXS-05.
  • Personalized medicine trends offer Axsome opportunities for tailored, effective therapies.

What critics are saying

  • Increased competition in CNS treatments may impact Axsome's market share.
  • Potential delays in AXS-07 approval could affect launch timeline and revenue.
  • Reliance on key products like AXS-05 makes Axsome vulnerable to setbacks.

What makes Axsome Therapeutics Inc unique

  • Axsome focuses on CNS disorders, addressing unmet medical needs with innovative therapies.
  • AXS-05, a flagship product, has FDA Breakthrough Therapy Designation for depression.
  • Axsome's balanced portfolio includes both clinical and research stage products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Company News

Insider Monkey
Feb 23rd, 2025
Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma Stock So Far in 2025

Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma stock So Far in 2025.

Investing.com
Dec 19th, 2024
Amgen stock touches 52-week low at $257.77 amid market shifts

The firm sees potential in Sarepta's Elevidys for Duchenne muscular dystrophy, Legend's ability to double its manufacturing capacity, and Axsome's anticipated launch of AXS-07 for migraines.

MarketBeat
Dec 13th, 2024
Captrust Financial Advisors Invests $514,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Captrust Financial Advisors invests $514,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

MarketBeat
Dec 4th, 2024
Erste Asset Management GmbH Invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Erste Asset Management GmbH invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

MarketBeat
Dec 2nd, 2024
PDT Partners LLC Makes New $1.05 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

PDT Partners LLC makes new $1.05 million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM).